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1 |  INTRODUCTION
Immune checkpoint inhibitor- induced diabetes mellitus is 
a rare immune- related adverse event. This report illustrates 
clinical data and insulin secretory ability before and after the 
onset of immune checkpoint inhibitor- induced diabetes.
The programmed cell death- 1 (PD- 1) receptor is ex-
pressed on the surface of activated T cells and regulatory 
T cells, and is an immune checkpoint molecule. PD- 1 in-
teracts with two ligands, programmed cell death ligand- 1 
(PD- L1) and PD- L2 within the tumor microenvironment.1 
Engagement of PD- 1 through PD- L1 negatively regulates 
T cell– mediated immune responses. Immune checkpoint 
inhibitor (ICI) activates T- cell immunity and suppresses 
tumor growth.2 As the use of ICI therapy is expanding 
for treating many cancer types,3,4 the increase in immune- 
related adverse events (irAEs) has been obvious. It is im-
portant for cancer patients to pay careful attention to irAEs. 
The most common irAEs are rash, hypothyroidism, hepati-
tis, and gastroenteritis.4,5 Although the percentage of ICI- 
induced diabetes mellitus (ICI- induced DM) is rare (<1%), 
it is a life- threatening side effect without any means of 
early detection. Several studies reported that ICI- induced 
DM had several characteristics, the first was rapid- onset 
of severe hyperglycemia, the second was diabetic ketoac-
idosis (DKA) or very low to absent C- peptide levels, and 
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Abstract
Immune checkpoint inhibitor- induced diabetes mellitus is a rare immune- related ad-
verse event. This report illustrates clinical data and insulin secretory ability before 
and after the onset of immune checkpoint inhibitor- induced diabetes.
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the third was persistent insulin dependence after the onset 
of diabetes.6- 8 Most cases are caused by anti- PD- 1 or anti- 
PD- L1 therapy, and ICI- induced DM by anti- cytotoxic T- 
lymphocyte- associated protein 4 (CTLA- 4) is rare. It has 
also been reported that the combination of anti- PD- 1 an-
tibody and CTLA- 4 inhibitor causes faster onset of ICI- 
induced DM than anti- PD- 1 antibody monotherapy.6,7 In 
non- obese diabetic mice, anti- PD1 inhibitor administration 
rapidly induced diabetes, but anti- CTLA- 4 inhibitors did 
not.9 Here, we report two cases in which insulin secretion 
was monitored before and after the onset of ICI- induced 
DM in patients treated with nivolumab.
2 |  CASE REPORTS
2.1 | Case 1
A 76- year- old woman with gastric cancer had undergone 
total gastrectomy and pancreatoduodenectomy after preop-
erative chemotherapy. Although adjuvant chemotherapy was 
given after surgery, the gastric cancer recurred 2 years after 
surgery. She then received nivolumab (3 mg/kg) as a third- 
line therapy. She had no prior personal or family history of 
diabetes mellitus. At the time of nivolumab treatment, fasting 
blood glucose levels were 5.9 mmol/L and HbA1c 6.1%. Her 
body mass index (BMI) was 17.5 kg/m².
One hundred and 3  days after initial treatment with 
nivolumab, the patient was admitted to our hospital after 
5  days of progressive general fatigue, thirst, and polyuria. 
She had no fever or other symptoms, suggesting she was 
free from a focal infection or systemic inflammation. On 
physical examination, she was alert. Laboratory data at the 
time of admission revealed hyperglycemia (blood glucose 
levels of 33.5 mmol/L) with ketosis (arterial blood pH 7.35, 
ketone body concentration 7620  μmol/L, the concentration 
of acetoacetate 1019  μmol/L, and the concentration of β- 
hydroxybutyrate 5925 μmol/L). HbA1c was 9.0%, and serum 
C- peptide levels were 0.05 nmol/L. Her pancreatic enzymes, 
thyroid hormones, and cholesterol levels were within the 
normal ranges. Abdominal computed tomography imaging 
showed porta hepatis and para- aortic lymph node swelling, 
but no significant findings in the pancreas. Upon additional 
blood testing, she was not found to have serum anti- glutamic 
acid decarboxylase, anti- insulinoma- associated antigen- 2, 
anti- zinc transporter antibody 8, or anti- islet cell antibodies. 
Her human leukocyte antigen typing was DRB1 *08: 02- 
DQB1 *03: 02 and DRB1 *14: 54- DQB1 *05: 03. She did 
not have the type 1 DM- associated genotype. Acute- onset 
ICI- induced DM was diagnosed from her clinical course and 
laboratory data.
The levels of HbA1c and serum C- peptide levels were 
monitored before and after the onset of ICI- induced DM. 
HbA1c increased from 6.1 to 9.0% during 103 days of her 
course. Fasting C- peptide levels increased from 0.53 to 
0.78  nmol/L, fasting blood glucose levels decreased from 
5.9 to 5.2  mmol/L (Figure  1), 0– 28  days after the start of 
nivolumab treatment, then serum C- peptide levels decreased 
to 0.05 nmol/L at the onset of ICI- induced DM. After admis-
sion, serum C- peptide levels were depleted (Figure 1). She 
was initially treated with intravenous fluids and continuous 
insulin infusion, which was changed to subcutaneous mul-
tiple daily injections with a combination of rapid and long- 
acting insulins.
2.2 | Case 2
A 68- year- old woman with stage IVA gingival cancer had 
been receiving tegafur, gimeracil, oteracil potassium therapy, 
and neoadjuvant chemotherapy. Tegafur, gimeracil, oteracil 
potassium therapy, and radiation therapy were conducted 
after surgical resection of the hemimandible; however, gin-
gival cancer spread to cervical lymph nodes and larynx, 
and she felt difficulty in swallowing. Then, she was treated 
with nivolumab (3  mg/kg) as a third- line therapy. At the 
time of nivolumab treatment, fasting blood glucose levels 
were 6.7 mmol/L and HbA1c 5.2%. Her BMI was 16.8 kg/
m². Three hundred days after the first nivolumab administra-
tion, she presented to our hospital complaining of persistent 
appetite loss and general fatigue for several days. She had 
acute airway obstruction and cardiopulmonary arrest due to 
mucous sputum filling in larynx when waiting for a medi-
cal examination. Even after cardiopulmonary resuscitation, 
hypoxic encephalopathy led to prolonged unconsciousness. 
Blood glucose levels were 36.3  mmol/L, and HbA1c was 
9.5%. Serum C- peptide levels were 0.13 nmol/L, and urinary 
C- peptide level excretion was 11.9  μg/day. Her pancreatic 
enzymes were within the normal range. The ketone body 
measurements were not performed at onset. Abdominal com-
puted tomography imaging showed no significant findings 
in the pancreas. Anti- glutamic acid decarboxylase and anti- 
IA- 2 antibodies were negative. Human leukocyte antigen 
typing showed DRB1*04:03- DQB1*03:02, DRB1*15:01- 
DQB1*06:02, and she did not have the type 1 DM- associated 
genotype. We could not evaluate ketosis but diagnosed 
acute- onset ICI- induced DM from her clinical course and 
laboratory data.
Because she did not recover from the comatose state, a 
nasogastric tube was inserted for feeding. Multiple daily in-
jections of long- acting and ultra- rapid insulin were used to 
control her blood glucose levels. Although nivolumab was 
effective for preventing cancer progression, this treatment 
was discontinued.
The time courses of HbA1c and serum C- peptide levels 
were monitored before the onset of ICI- induced DM. HbA1c 
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increased from 5.2 to 9.5% in the period of 300 days. Fasting 
C- peptide levels increased from 0.38 to 0.47 nmol/L, and fast-
ing blood glucose levels decreased from 6.7 to 6.2 mmol/L, 
0– 28 days after nivolumab treatment, then serum C- peptide 
levels decreased to 0.13 nmol/L at the onset of ICI- induced 
DM (Figure 1).
3 |  DISCUSSION
We report two cases of acute- onset ICI- induced DM in 
which the longitudinal course of fasting C- peptide levels 
and corresponding fasting blood glucose levels was as-
sessed before and after the administration of nivolumab 
therapy. As far as we are aware, most of previous reports 
have measured blood glucose levels and serum C- peptide 
levels after the onset of ICI- induced DM. Few literatures 
have reported the longitudinal course of C- peptide levels 
and corresponding fasting blood glucose levels before and 
after the onset of ICI- induced DM. Our cases showed that 
insulin secretion increased 1 month after nivolumab admin-
istration and remained in the normal range until the onset 
of ICI- induced DM. Furthermore, fasting plasma glucose 
level slightly decreased and the HbA1c level increased in 
both cases without any change in nutritional status before 
the onset. Nivolumab therapy also aggravates pre- existing 
diabetes with incompletely deficient insulin secretion.10 
It was suggested that mild glucose intolerance may have 
F I G U R E  1  Longitudinal course of 
HbA1c, serum C- peptide levels, and fasting 
blood glucose levels. HbA1c increased from 
6.1 to 6.5%, the fasting C- peptide levels 
increased from 0.53 to 0.78 nmol/L and 
fasting blood glucose levels decreased from 
5.9 to 5.2 mmol/L, 0– 28 days after the start 
of nivolumab (Nivo) treatment, then HbA1c 
increased to 9.0%, serum C- peptide levels 
decreased to 0.05 nmol/L and fasting blood 
glucose levels increased to 33.5 mmol/L at 
the onset of immune checkpoint inhibitor- 
induced diabetes. After admission, serum 
C- peptide levels were depleted (Case 1). 
HbA1c increased from 5.2 to 5.6%, the 
fasting C- peptide levels increased from 0.38 
to 0.47 nmol/L and fasting blood glucose 
levels decreased from 6.7 to 6.2 mmol/L, 
0– 28 days after nivolumab treatment, 
then HbA1c increased to 9.5%, serum 
C- peptide levels decreased to 0.13 nmol/L 
and fasting blood glucose levels increased 
to 36.3 mmol/L at the onset of immune 
checkpoint inhibitor- induced diabetes (Case 
2). X: at admission. *: random plasma 
glucose
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occurred while insulin secretion was maintained in the 
normal range before insulin secretion decreased markedly. 
The contribution of postprandial hyperglycemia is predom-
inant in patients with well- controlled HbA1c, over fasting 
hyperglycemia.11 Postprandial glucose levels could not be 
assessed in our cases; however, we speculate that increased 
HbA1c and serum C- peptide levels reflect elevated post-
prandial blood glucose levels.
Some studies have demonstrated that irAEs are associated 
with improved survival in melanoma or non- small cell lung 
cancer patients treated with nivolumab.12,13 33 isolated re-
ports of ICI- induced DM that included the effectiveness of 
anti- PD- 1 antibody therapy can be found in the literature 
(Table  1). The overall response rate (complete plus partial 
response) was 52% (5 complete and 12 partial responses in 33 
cases). ICI- induced DM may be a predictive marker for du-
rable clinical benefit in cancer patients, although the mecha-
nisms underlying the association of ICI- induced DM with the 
outcome of anti- PD- 1 antibody therapy are unknown. In our 
cases, although no recurrence was observed and the response 
to anti- PD- 1 antibody therapy was stable disease, anti- PD- 1 
antibody treatment was discontinued because of a patient or 
family's request.
In a Japanese national survey of ICI- induced DM, 
HbA1c and blood pH were higher, and fasting plasma glu-
cose levels tended to be lower at the onset of ICI- induced 
DM than conventional type 1 DM.39 Baden M et al. re-
ported that diabetic ketoacidosis was observed in 39% 
of ICI- induced DM patients in Japan, while Akturk. HK 
et al40 reported that diabetic ketoacidosis was observed 
76% of ICI- induced DM patients in their systematic review 
(Table  2). It might be one of the reasons for this differ-
ence that the higher positive rate of islet- related autoan-
tibodies in Akturk's report than Baden's report (presence 
of islet- related autoantibody; 50.7% in Akturk's report vs 
4.8% in Baden's report). Similar to the report of Baden, 
M. et al., HbA1c was as high as 9.0% or more, though di-
abetic ketoacidosis was not observed and islet- related au-
toantibodies were negative in our cases. Recent research 
revealed that patients who had islet- related autoantibodies 
were reported to develop ICI- induced DM rapidly.6,40,41 In 
Table  1, islet- related autoantibodies were negative in 17 
cases and positive in 13 cases. The duration to the onset 
of ICI- induced DM was significantly longer in islet- related 
autoantibody- negative cases (the average duration between 
ICI initiation and DM development; 176 ± 134 days in neg-
ative group vs 31 ± 20 days in positive group, p = 0.000, 
Man- Whitney test; Table 1). Our cases did not have islet- 
related autoantibodies, and the duration to the onset of 
ICI- induced DM was more than 3 months from the initial 
administration of nivolumab.
There is no standard version of case definitions for ICI- 
induced DM. ICI- induced DM often characterized by the 
presence of diabetic ketoacidosis or very low to absent C- 
peptide levels and insulin dependence after the onset of dia-
betes.6- 8 Baden, M. et al39 suggested that C- peptide levels of 
acute- onset type 1 diabetes were 0.15 (0.07– 0.23) nmol/L, 
while those of fulminant type 1 diabetes were 0.07 ( ± 0.06) 
nmol/L in Japanese patients with ICI treatment. Tsang V. H. 
M. et al8 reported that C- peptide levels were 0.41  nmol/L 
several months after diagnosis of ICI- induced DM. However, 
specific cutoff values for C- peptide levels in ICI- induced 
DM have not been determined.7 In the current cases, ICI- 
induced DM was diagnosed by the clinical symptoms and 
laboratory data. Hyperglycemia symptoms such as general 
fatigue, thirst, and polyuria appeared for several days in 
both cases. The serum C- peptide levels were inappropriately 
low (case1: 0.05 nmol/L and case2: 0.13 nmol/L), and both 
Akturk. H. K., et al, 
201940
n = 71
Baden, M., et al, 
2019a 39
n = 22
Age, years (SD) 61.7 (12.2) 63 (12)
Gender (Female; %) 45 41
immune checkpoint inhibitor 
(nivolumab; %)
53.5 100
Duration to the onset of immune 
checkpoint inhibitor- induced 
diabetes mellitus, days (SD)
83.5 (88.5) 121(21)
Diabetic ketoacidosis (%) 76 39
Plasma glucose, mmol/L (SD) 33.4 (11.5) 34.2 (13.8)
HbA1c, % (SD) 7.8 (2.2) 8.1 (1.3)
Presence of islet- related 
autoantibody (%)
50.7 4.8
aall patients were Japanese.
T A B L E  2  Clinical characteristics 
of immune checkpoint inhibitor- induced 
diabetes mellitus
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patients were insulin dependent for over 1 year after the onset 
of ICI- induced DM. In case 2, although the course of insulin 
secretion after the onset could not be assessed, ICI- induced 
DM was diagnosed because the serum C- peptide levels at the 
onset had already markedly decreased and the patient was 
insulin dependent.
As ICI- induced DM is a rare, but life- threatening side 
effect of nivolumab, close monitoring of blood glucose lev-
els is recommended for the early diagnosis of ICI- induced 
DM. Pathogenic mechanisms underlying the development 
of ICI- induced DM and predictive markers for selection of 
patients who have increased risk of the onset of ICI- induced 
DM have not been elucidated. Monitoring clinical data in-
cluding insulin secretory ability might help in early detection 
of ICI- induced DM and understanding clinical features of 
the development of DM during ICI treatment. Our two cases 
showed that insulin secretion was maintained in the normal 
range and temporarily increased before the onset of ICI- 
induced DM. Accumulating cases of ICI- induced DM can be 
helpful to identify predictive markers for early diagnosis and 
prevent this side effect.
The data that support the findings of this study are 
available on request from the corresponding author. The 
data are not publicly available due to privacy or ethical 
restrictions.
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